VRCA Q3 2023 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-64.9% YoY

Gross Profit

$3M95.0% margin

Operating Income

-$24M-819.9% margin

Net Income

-$25M-850.3% margin

EPS (Diluted)

$-5.38

QoQ Revenue Growth

+1502.7%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$97M

Total Liabilities

$55M

Stockholders' Equity

$42M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$8M	-64.9%
Gross Profit	$3M	$8M	-66.0%
Operating Income	-$24M	$1M	-1751.7%
Net Income	-$25M	$83,000	-29981.9%

Revenue Segments

Product

$3M96%

Collaboration

$125,0004%